Nutromics received FDA breakthrough device designation for its wearable patch designed to track vancomycin levels in real time. The company’s aim is to reduce reliance on periodic blood draws used to manage the antibiotic’s dosing precision. The designation highlights the regulator’s interest in practical tools that address the clinical complexity of drugs requiring therapeutic drug monitoring. If successful, the patch could change workflows in hospitals by improving dosing continuity and potentially reducing monitoring burden. For the biotech and medtech ecosystem, breakthrough status also tends to accelerate development timelines, reimbursement discussions, and additional validation studies needed for broader clinical adoption.